Delivery Order SPE2DB22D2211-SPE2DB25FSCYA
- Not listed
- The Defense Logistics Agency awarded a $5,864.45 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors on September 4, 2025, with completion targeted for September 5, 2025. This non-competitive delivery order represents a firm fixed price transaction under AmerisourceBergen's larger contract vehicle with DLA. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. Emgality is a CGRP monoclonal antibody...
- The Defense Logistics Agency awarded a delivery order valued at $1,037.40 to AmerisourceBergen Drug Corp for the supply of Emgality 120 mg/ml in pre-filled pen format. This non-competitive, firm fixed-price delivery order was issued on September 9, 2025, with an ultimate completion date of September 10, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Emgality is a calcitonin gene-related peptide (CGRP) antagonist used for migraine prevention,...
- The Defense Logistics Agency awarded a delivery order valued at $1,309.49 to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors on May 20, 2025, with an ultimate completion date of May 21, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procedures. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Emgality is a migraine prevention medication, reflecting the company's role as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Emgality 120 mg/ml pen injectors, valued at $3,458.00. This firm fixed-price contract, which is non-set-aside and competitively awarded, is scheduled for completion by August 7, 2025, with performance occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,037.40 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors. This non-set-aside, competitively awarded contract was issued on September 16, 2025, with an ultimate completion date of September 17, 2025, and reflects a firm fixed-price delivery order structure. The product will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Emgality is a CGRP monoclonal antibody...
- The Defense Logistics Agency awarded a $2,348.61 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors on September 4, 2025, with a completion date of September 5, 2025. This competitively awarded, firm fixed-price contract has no set-aside designation and is performed at the contractor's facility in Conshohocken, Pennsylvania. Emgality is a calcitonin gene-related peptide monoclonal antibody used in migraine prevention, reflecting the Defense Logistics Agency's...
- The Defense Logistics Agency awarded a $19,429.58 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors on September 19, 2025, with completion targeted for September 22, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Emgality is a migraine prevention medication used in military and federal healthcare systems to treat...
- The Defense Logistics Agency awarded a delivery order valued at $1,401.40 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen (injectable migraine treatment) with a completion date of September 17, 2025. This competitively awarded, firm fixed-price delivery order represents a single transaction within AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The contract specifies performance at the company's Conshohocken, Pennsylvania facility, where...
- The Defense Logistics Agency (DLA) awarded a $3,457 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors on September 18, 2025, with an ultimate completion date of September 19, 2025. This competitive, firm fixed-price contract was issued without set-aside designation and represents a child order under AmerisourceBergen's larger contract vehicle with DLA. The product—Emgality (erenumab)—is a monoclonal antibody used for migraine prevention, reflecting the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pens on September 11, 2025, with a ceiling value of $1,037.40 under a firm fixed price contract type. This order represents a non-competitive set-aside delivery against AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSCYADelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,116.22 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Emgality 120 mg/ml in pen format. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under an open competition process. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 15, 2025. Emgality is a monoclonal antibody treatment used for migraine prevention and cluster headaches, indicating this order supports the federal government's pharmaceutical supply chain for military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. That prime IDV serves as a comprehensive global pharmaceutical support vehicle, enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen's role as a critical pharmaceutical distributor for federal medical procurement demonstrates the Defense Logistics Agency's reliance on established prime vendors to fulfill specialized medication requirements across the military healthcare system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.1k | 8/14/25 |